VEGF-D Activators
VEGF-D activators are compounds that can influence signaling pathways or transcription factors leading to increased expression or activity of VEGF-D. These activators can act at the genomic level, such as 5-Aza-2'-deoxycytidine, which induces hypomethylation of DNA, enhancing the transcription of the VEGF-D gene. Others, like cobalt(II) chloride and deferoxamine, operate through the stabilization of HIFs, which are transcription factors that under hypoxic conditions bind to response elements on the VEGF-D gene to stimulate its expression.
Activation of VEGF-D is also associated with signal transduction pathways, where compounds such as EGF and insulin lead to the activation of the PI3K/Akt pathway, which is known to result in increased expression of VEGF-D. Similarly, Phorbol 12-myristate 13-acetate (PMA) utilizes the PKC pathway to influence the transcription of VEGF-D. These mechanisms are interconnected with various cellular processes and signaling cascades that culminate in the elevated synthesis and activity of VEGF-D, underscoring the complexity and the multitude of potential regulatory controls exerted by these chemical activators.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cobalt(II) chloride | 7646-79-9 | sc-252623 sc-252623A | 5 g 100 g | $64.00 $176.00 | 7 | |
Cobalt(II) chloride can stabilize hypoxia-inducible factors (HIFs) under normoxic conditions. Stabilized HIFs can transactivate VEGF-D gene expression through hypoxia response elements in its promoter. | ||||||
Dimethyloxaloylglycine (DMOG) | 89464-63-1 | sc-200755 sc-200755A sc-200755B sc-200755C | 10 mg 50 mg 100 mg 500 mg | $84.00 $301.00 $374.00 $779.00 | 25 | |
Dimethyloxalylglycine inhibits prolyl hydroxylases, leading to HIF-1 stabilization. HIF-1 can bind to the hypoxia-response element on the VEGF-D gene, enhancing its transcription. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
This DNA methyltransferase inhibitor can cause demethylation and subsequent activation of certain genes, potentially including VEGF-D, resulting in increased expression. | ||||||
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Insulin can stimulate the PI3K/Akt signaling pathway, which has been associated with increased VEGF-D expression through enhanced transcription. | ||||||
Deferoxamine | 70-51-9 | sc-507390 | 5 mg | $255.00 | ||
Deferoxamine mimics hypoxic conditions by chelating iron, thereby stabilizing HIFs which can enhance VEGF-D expression. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which can enhance the transcription of VEGF-D through PKC-mediated signaling pathways. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride can activate the Wnt/β-catenin pathway, indirectly promoting the expression of VEGF-D due to pathway interactions. | ||||||
β-Estradiol | 50-28-2 | sc-204431 sc-204431A | 500 mg 5 g | $63.00 $182.00 | 8 | |
β-Estradiol binds its receptor, leading to transcriptional activation of various genes, which may include VEGF-D, thereby increasing its levels. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
PGE2 interacts with its receptors, leading to cAMP increase and PKA activation, which may result in upregulation of VEGF-D expression. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid binds to retinoic acid receptors and can upregulate gene expression, possibly including VEGF-D, through genomic signaling. | ||||||